Injectable Bulking Agent to Treat Postprostatectomy Urinary Incontinence: A Safety and Effectiveness Pilot Study

Figure 1

Magnetic resonance imaging (MRI) views of bulking agent. 1.5 T Siemens Avanto MRI:T2 Blade 3,5mm sagittal, T1 space coronal 0.9mm, T2 TSE transversal 3.5mm, T2 TSE coronal oblique 3.5mm, and T2 TSE coronal 3.5mm. Technical aspects: Field Of View 240mm, distance 30%, phase right to left, resolution 320, and phase resolution 86%.

(a) Patient with 5 submucosal urethral injections at 1, 3, 5, 7, and 9 o’clock, total amount of Opsys® injected is 2.5 mL. Two transverse views. Lateral and dorsal of the urethra are white spots which shows bulking agent

(b) Patient with 5 submucosal urethral injections at 2, 5, 6, 8, and 10 o’clock, total amount of Opsys® injected is 4.0 mL. Only 1 transverse view on MRI shows a white spot which shows the bulking agent